Trials / Completed
CompletedNCT00857961
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
A Phase II, Randomised, Four-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered Dose (MD) Lotion® Formulations and Doses in Hypogonadal Men
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone MD-Lotion | Administered Topically |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2009-03-09
- Last updated
- 2011-01-07
- Results posted
- 2011-01-07
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00857961. Inclusion in this directory is not an endorsement.